DK2462162T3 - Antistoffer som specifikt binder til A-beta-oligomerer og anvendelse deraf - Google Patents

Antistoffer som specifikt binder til A-beta-oligomerer og anvendelse deraf Download PDF

Info

Publication number
DK2462162T3
DK2462162T3 DK10806239.9T DK10806239T DK2462162T3 DK 2462162 T3 DK2462162 T3 DK 2462162T3 DK 10806239 T DK10806239 T DK 10806239T DK 2462162 T3 DK2462162 T3 DK 2462162T3
Authority
DK
Denmark
Prior art keywords
antibody
amino acid
seq
acid sequence
ser
Prior art date
Application number
DK10806239.9T
Other languages
English (en)
Inventor
Tatsuki Yokoseki
Yasuhide Okamoto
Makoto Umeda
Naofumi Takamatsu
Toshiyuki Ito
Yukiho Imai
Shinobu Fujii
Original Assignee
Immunas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunas Pharma Inc filed Critical Immunas Pharma Inc
Application granted granted Critical
Publication of DK2462162T3 publication Critical patent/DK2462162T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Claims (4)

1. Antistof, eller antigen-bindende fragment deraf, som genkender en isoleret A-beta-oligomer som et antigen, hvor antistoffet ikke binder til en A-beta-monomer og omfatter (a) en H-kæde med aminosyresekvensen ifølge SEQ ID NO: 38 som CDR1, aminosyresekvensen ifølge SEQ ID NO: 40 som CDR2, og aminosyresekvensen ifølge SEQ ID NO: 42 som CDR3; og (b) en L-kæde med aminosyresekvensen ifølge SEQ ID NO: 44 som CDR1, aminosyresekvensen ifølge SEQ ID NO: 46 som CDR2, og aminosyresekvensen ifølge SEQ ID NO: 48 som CDR3, til anvendelse ved en fremgangsmåde til forebyggelse og/eller behandling af Alzheimer's sygdom.
2. Antistof eller antigen-bindende fragment til anvendelse ved en fremgangsmåde til forebyggelse og/eller behandling af Alzheimer's sygdom i overensstemmelse med krav 1, hvor antistoffet eller det antigen-bindende fragment omfatter en H-kæde med aminosyresekvensen ifølge SEQ ID NO: 106 som VH; og en L-kæde med aminosyresekvensen ifølge SEQ ID NO: 108 som VL.
3. Antistof til anvendelse ved en fremgangsmåde til forebyggelse og/eller behandling af Alzheimer's sygdom ifølge ethvert af kravene 1 til 2, hvor antistoffet er et kimært antistof eller et humaniseret antistof.
4. Farmaceutisk sammensætning til anvendelse ved en fremgangsmåde til forebyggelse og/eller behandling af Alzheimer's sygdom omfattende antistoffet eller det antigen-bindende fragment ifølge ethvert af kravene 1 til 3, og et farmaceutisk acceptabelt bærestof.
DK10806239.9T 2009-08-06 2010-08-05 Antistoffer som specifikt binder til A-beta-oligomerer og anvendelse deraf DK2462162T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23179709P 2009-08-06 2009-08-06
US28255010P 2010-02-26 2010-02-26
PCT/JP2010/004926 WO2011016239A1 (en) 2009-08-06 2010-08-05 Antibodies that specifically bind to a beta oligomers and use thereof

Publications (1)

Publication Number Publication Date
DK2462162T3 true DK2462162T3 (da) 2017-01-16

Family

ID=43544148

Family Applications (1)

Application Number Title Priority Date Filing Date
DK10806239.9T DK2462162T3 (da) 2009-08-06 2010-08-05 Antistoffer som specifikt binder til A-beta-oligomerer og anvendelse deraf

Country Status (7)

Country Link
US (1) US8613924B2 (da)
EP (1) EP2462162B1 (da)
JP (1) JP5599454B2 (da)
CN (1) CN102596997B (da)
DK (1) DK2462162T3 (da)
ES (1) ES2614949T3 (da)
WO (1) WO2011016239A1 (da)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103408661B (zh) * 2007-01-05 2016-04-06 苏黎世大学 提供疾患特异性结合分子和靶的方法
IL199534A (en) 2007-01-05 2013-01-31 Univ Zuerich An isolated human antibody capable of detecting a neoepitope in a disease-related protein, a polynucleotide encoding an antibody, a vector containing the polynucleotide, a host cell containing the polynucleotide or vector, a preparation containing the antibody and related methods and uses.
CN101965365A (zh) * 2007-10-19 2011-02-02 伊缪纳斯制药株式会社 能够特异性结合Aβ寡聚体的抗体及其应用
CA2714413C (en) 2008-02-08 2017-01-24 Immunas Pharma, Inc. Antibody capable of binding specifically to ab-oligomer, and use thereof
EP2321348A2 (en) * 2008-07-09 2011-05-18 University of Zürich Method of promoting neurogenesis
US9085614B2 (en) 2008-08-01 2015-07-21 Immunas Pharma, Inc. Antibodies that specifically bind to Aβ oligomers and uses thereof
PL2949666T3 (pl) 2008-12-19 2019-07-31 Biogen International Neuroscience Gmbh Ludzkie przeciwciała przeciwko alfa-synukleinie
EP2419447B1 (en) 2009-04-17 2017-08-23 Immunas Pharma, Inc. Antibodies that specifically bind to a beta oligomers and use thereof
DK2462161T3 (da) 2009-08-06 2017-06-06 Immunas Pharma Inc Antistoffer der specifikt binder til A-beta-oligomerer og anvendelse deraf
US9320793B2 (en) * 2010-07-14 2016-04-26 Acumen Pharmaceuticals, Inc. Method for treating a disease associated with soluble, oligomeric species of amyloid beta 1-42
SI2723379T1 (sl) 2011-06-23 2019-03-29 Biogen International Neuroscience Gmbh Molekule, ki se vežejo ma anti alfa-sinuklein
US9588129B2 (en) * 2013-03-15 2017-03-07 Amira Medical Technologies Inc. Methods for analyzing blood to detect diseases associated with abnormal protein aggregation
JP2017536102A (ja) * 2014-10-16 2017-12-07 ジェネンテック， インコーポレイテッド 抗アルファ−シヌクレイン抗体及び使用方法
MA41115A (fr) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
EA202090555A1 (ru) 2017-08-22 2020-06-08 Байоджен Ма Инк. Фармацевтические композиции, содержащие антитела к бета-амилоиду
CN108020673A (zh) * 2017-11-15 2018-05-11 首都医科大学宣武医院 Aβ试剂盒、检测方法及应用
KR20200144551A (ko) * 2018-03-28 2020-12-29 악손 뉴로사이언스 에스이 알츠하이머병을 검출하고 치료하는 항체-기반 방법
CN117343173A (zh) * 2019-03-07 2024-01-05 瑞阳(苏州)生物科技有限公司 人IL-1β蛋白结合分子及其编码基因和应用
AU2020347483A1 (en) * 2019-09-10 2022-03-31 Ac Immune Sa Novel molecules for diagnosis
CN114573694B (zh) * 2020-12-01 2023-09-01 深圳华柏生物科技有限公司 一种抗IL13Rα2抗体及其制备方法和用途

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0239102A3 (en) 1986-03-28 1989-07-12 Tsuji, Kimiyoshi Process for the formation of human-human hybridoma
ES2108048T3 (es) 1990-08-29 1997-12-16 Genpharm Int Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
CA2140638C (en) 1992-07-24 2010-05-04 Raju Kucherlapati Generation of xenogeneic antibodies
CA2161351C (en) 1993-04-26 2010-12-21 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
US6218506B1 (en) 1997-02-05 2001-04-17 Northwestern University Amyloid β protein (globular assembly and uses thereof)
US20030068316A1 (en) 1997-02-05 2003-04-10 Klein William L. Anti-ADDL antibodies and uses thereof
AR022952A1 (es) 1999-03-19 2002-09-04 Smithkline Beecham Corp ANTICUERPO MONOCLONAL DE ROEDOR ESPECIFICAMENTE NEUTRALIZANTE PARA LA INTERLEUQUINA-18 HUMANA , UN FRAGMENTO FAB NEUTRALIZANTE o FRAGMENTO F(AB')2, UNA REGION DE COMPLEMENTARIEDAD DE CADENA LIGERA DE INMONOGLOBULINA(CDR), UNA MOLECULA DE ACIDO NUCLEICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE, EL
AUPR617901A0 (en) 2001-07-06 2001-08-02 Pacmab Pty Ltd Method for treating multiple myeloma
JP4729717B2 (ja) 2001-08-03 2011-07-20 株式会社医学生物学研究所 ＧＭ１ガングリオシド結合型アミロイドβタンパク質を認識する抗体、及び該抗体をコードするＤＮＡ
WO2010012004A2 (en) 2008-07-25 2010-01-28 The Regents Of The University Of California Monoclonal antibodies specific for pathological amyoid aggregates common to amyloids formed from proteins of differing sequence
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
US8394379B2 (en) 2003-05-15 2013-03-12 Iogenetics, Llc Targeted cryptosporidium biocides
JP2008513732A (ja) * 2004-07-02 2008-05-01 ノースウエスタン ユニバーシティ アミロイドβ（Ａｂｅｔａ）の病理学的なアセンブリを標的とするモノクローナル抗体
WO2006047254A1 (en) 2004-10-22 2006-05-04 Regents Of The University Of Minnesota Assemblies of oligomeric amyloid beta protein and uses thereof
CA2584859C (en) * 2004-10-25 2017-11-07 Merck & Co., Inc. Anti-addl antibodies and uses thereof
DK1830881T3 (da) * 2004-12-10 2010-09-20 Novimmune Sa Kombinationsterapier, som er målrettet mod multiple toll-like-receptorer og anvendelse deraf
PE20061401A1 (es) 2004-12-15 2006-12-23 Neuralab Ltd ANTICUERPOS Aß PARA MEJORAR LA COGNICION
US20110020237A1 (en) 2005-01-14 2011-01-27 Glabe Charles G Compositions and Methods for Inhibiting Drusen Formation and for Diagnosing or Treating Drusen-Related Disorders
KR20080021585A (ko) 2005-03-05 2008-03-07 애보트 게엠베하 운트 콤파니 카게 스크리닝 방법, 비확산성 ａ-베타 올리고머의 정제 방법,당해 비확산성 ａ-베타 올리고머에 대한 선택적 항체 및당해 항체의 제조 방법
US7741448B2 (en) 2005-06-21 2010-06-22 Medical & Biological Laboratories Co., Ltd. Antibody having inhibitory effect on amyloid fibril formation
EP1749839A1 (en) 2005-07-22 2007-02-07 Novoplant GmbH Antigen binding polypeptides against F4(K88) fimbriae
KR101413615B1 (ko) * 2006-03-23 2014-07-18 바이오악틱 뉴로사이언스 에이비 인간 프로토피브릴에 선택적인 개선된 항체 및 이의 용도
US20090232801A1 (en) 2007-05-30 2009-09-17 Abbot Laboratories Humanized Antibodies Which Bind To AB (1-42) Globulomer And Uses Thereof
US20100291071A1 (en) 2008-08-01 2010-11-18 Immunas Pharma, Inc. Antibody Specific Binding to A-Beta Oligomer and the Use
CN101965365A (zh) 2007-10-19 2011-02-02 伊缪纳斯制药株式会社 能够特异性结合Aβ寡聚体的抗体及其应用
CA2714413C (en) 2008-02-08 2017-01-24 Immunas Pharma, Inc. Antibody capable of binding specifically to ab-oligomer, and use thereof
US9085614B2 (en) 2008-08-01 2015-07-21 Immunas Pharma, Inc. Antibodies that specifically bind to Aβ oligomers and uses thereof
EP2419447B1 (en) 2009-04-17 2017-08-23 Immunas Pharma, Inc. Antibodies that specifically bind to a beta oligomers and use thereof
DK2462161T3 (da) 2009-08-06 2017-06-06 Immunas Pharma Inc Antistoffer der specifikt binder til A-beta-oligomerer og anvendelse deraf

Also Published As

Publication number Publication date
EP2462162A4 (en) 2013-05-22
US20120156193A1 (en) 2012-06-21
ES2614949T3 (es) 2017-06-02
JP5599454B2 (ja) 2014-10-01
CN102596997B (zh) 2015-06-03
CN102596997A (zh) 2012-07-18
JP2013500940A (ja) 2013-01-10
EP2462162B1 (en) 2016-10-12
US8613924B2 (en) 2013-12-24
EP2462162A1 (en) 2012-06-13
WO2011016239A1 (en) 2011-02-10

Similar Documents

Publication Publication Date Title
DK2462162T3 (da) Antistoffer som specifikt binder til A-beta-oligomerer og anvendelse deraf
DK2462161T3 (da) Antistoffer der specifikt binder til A-beta-oligomerer og anvendelse deraf
DK2419447T3 (da) Antistoffer, der specifikt binder til a beta-oligomerer og anvendelse deraf
KR101616136B1 (ko) Ａβ 올리고머에 특이적으로 결합하는 항체 및 그의 이용
CA2702880A1 (en) Antibody capable of specifically binding to a beta oligomer, and use thereof
US9085614B2 (en) Antibodies that specifically bind to Aβ oligomers and uses thereof